RSV F Vaccine informational analysis completed in fourth quarter of 2017RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrolleesFiling of RSV F Vaccine BLA anticipated by late 2019NanoFlu Vaccine data package to be completed and released in February 2018
GAITHERSBURG, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M adjuvant (NanoFlu).... More